New drug aims to shrink HER2 breast tumors before surgery
NCT ID NCT07196774
First seen Jun 25, 2026 · Last updated Jul 31, 2026 · Updated 3 times
Summary
This phase 3 trial is testing a new drug called SHR-A1811 against a standard chemotherapy combination for women with early-stage or locally advanced HER2-positive breast cancer. About 740 participants will receive either the new drug or standard treatment before surgery. The main goal is to see if the new drug leads to a complete disappearance of cancer in the breast tissue removed during surgery.
What this could mean
Our plain-language read of the trial. This is informational only — not medical advice or a prediction.
- Active substance
- SHR-A1811 (an antibody-drug conjugate)
- What this could lead to
- If successful, SHR-A1811 could offer a more targeted, potentially less toxic neoadjuvant option for HER2-positive breast cancer, improving the chance of a complete response before surgery.
- What could go wrong
- This is a phase 3 trial, but results are not yet known. SHR-A1811 may not outperform the standard regimen, and side effects could be similar or different. Long-term benefits like survival are still being followed.
This is an AI summary of the original study and may miss details. Read our disclaimer.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for EARLY-STAGE OR LOCALLY ADVANCED HER2-POSITIVE BREAST CANCER are added.
By submitting, you agree to our Terms of use
Conditions
The condition(s) this trial relates to.
As listed by the trial registrant
The condition terms exactly as the trial's registrant entered them.
Contacts and locations
Locations
-
Fudan University Shanghai Cancer Center
Shanghai, Shanghai Municipality, 200032, China
-
Shengjing Hospital, China Medical University
Shenyang, Liaoning, 110000, China